Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
Adjunctive treatment of seizures in patients 2 years of age and older with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initiation:** Typically 5 mg twice daily.
* **Titration:** Increase dose gradually as tolerated, usually by 5-10 mg every week, to a maximum of 20 mg twice daily.
* **Maintenance:** Usual maintenance dose is 10-20 mg twice daily.
## Pediatric Dosing (2 years and older)
* **Initiation:** Typically 5 mg twice daily.
* **Titration:** Increase dose gradually as tolerated, usually by 2.5-5 mg every week, to a maximum based on weight:
* 20-40 kg: Maximum 10 mg twice daily.
* >40 kg: Maximum 20 mg twice daily.
* **Maintenance:** Usual maintenance dose is 5-20 mg twice daily depending on weight and tolerance.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are established, but lower doses may be warranted due to reduced clearance.
* **Renal Impairment:** Use with caution. No specific dose adjustments are established, but lower doses may be warranted.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
## Adverse Effects
**Most Common:** Somnolence, drooling, constipation, decreased appetite, fatigue, aggression, irritability, difficulty with coordination.
**Serious:** Severe respiratory depression, drug dependence and withdrawal symptoms, suicidal behavior and ideation, increased seizure frequency or severity, cognitive impairment, paradoxical reactions (e.g., excitation, agitation).
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Additive CNS depressant effects, increasing the risk of sedation, respiratory depression, and coma. Use concomitantly with extreme caution.
* **CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam concentrations, potentially leading to increased adverse effects.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam concentrations, potentially reducing efficacy.
* **Other Anticonvulsants:** Clobazam can affect the pharmacokinetics of other anticonvulsants; monitor for changes in efficacy or toxicity.
## Monitoring
* Monitor for somnolence and fatigue, especially during dose initiation and titration.
* Monitor for signs of respiratory depression, particularly in elderly patients or those with pre-existing respiratory conditions.
* Assess for behavioral changes, including suicidal thoughts or actions.
* Monitor for paradoxical reactions or increased seizure activity.
* Periodically reassess the need for continued treatment.
## Clinical Pearls
* Clobazam should be used as adjunctive therapy and not as monotherapy for LGS.
* Due to its long half-life, accumulation can occur, especially with continued dosing.
* Abrupt discontinuation can lead to withdrawal symptoms. Tapering is recommended.
* The oral suspension should be shaken well before use.
***
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the official prescribing information and relevant clinical guidelines for the most current and comprehensive details before making any treatment decisions.
